NGL Fine-Chem Ltd - Stock Valuation and Financial Performance

BSE: 524774 | NSE: NGLFINE | Pharmaceuticals & Drugs | Small Cap

NGL Fine-Chem Share Price

1,098.95 44.90 4.26%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on NGL Fine-Chem

Overall Rating
Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

NGL Fine-Chem stock performance -
1,098.95 -1,039.00-49.00% past year

Price Chart, Live Stock Chart, Technical Chart of
P/E Ratio (SA):
23.01
Market Cap:
678.9 Cr.
52-wk low:
962.7
52-wk high:
2,822.5

Is NGL Fine-Chem Ltd an attractive stock to invest in?

1. Is NGL Fine-Chem Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that NGL Fine-Chem Ltd is a average quality company.

2. Is NGL Fine-Chem Ltd undervalued or overvalued?

The key valuation ratios of NGL Fine-Chem Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is NGL Fine-Chem Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of NGL Fine-Chem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of NGL Fine-Chem:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
NGL Fine-Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE %
33%37.1%33.8%21.7%27.6%13.7%51.9%34.7%11.5%18.9%-
Value Creation
Index
1.41.71.40.61.00.02.71.5-0.20.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales
88.396.399.7114153152258319275329362
Sales YoY Gr.
-9%3.6%14%34.8%-0.7%69.7%23.4%-13.7%19.6%-
Adj EPS
11.318.522.918.62916.688.184.629.458.447.8
YoY Gr.
-63.1%24.2%-18.9%56%-42.7%430%-4%-65.2%98.4%-
BVPS (₹)
53.171.696.2116.6149.1163.8251.6334.4365425.4453.4
Adj Net
Profit
711.414.211.517.910.354.552.318.236.130
Cash Flow from Ops.
7.58.49.922.48.919.626.615.831.911.1-
Debt/CF from Ops.
1.81.72.31.23.11.40.61.913.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 15.7%16.5%8.4%19.6%
Adj EPS 20%15%-12.8%98.4%
BVPS26%23.3%19.1%16.5%
Share Price 30.7% 20% -19.5% -49.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
24.429.627.317.521.810.642.428.98.414.810.9
Op. Profit
Mgn %
16.922.825.61921.115.229.820.710.413.69.1
Net Profit
Mgn %
7.911.814.210.111.76.821.116.46.6118.2
Debt to
Equity
0.40.30.40.40.30.30.10.20.10.1-
Working Cap
Days
152160187198167184132166216186104
Cash Conv.
Cycle
6574816555794974997664

Recent Performance Summary

Sales growth is good in last 4 quarters at 18.98%

Return on Equity has declined versus last 3 years average to 10.90%

Sales growth has been subdued in last 3 years 8.41%

Net Profit has been subdued in last 3 years -12.82%

Latest Financials - NGL Fine-Chem Ltd.

Standalone Consolidated
TTM EPS (₹) 47.8 52.8
TTM Sales (₹ Cr.) 362 373
BVPS (₹.) 453.4 455.8
Reserves (₹ Cr.) 277 278
P/BV 2.42 2.41
PE 23.01 20.80
From the Market
52 Week Low / High (₹) 962.70 / 2822.50
All Time Low / High (₹) 0.40 / 3789.45
Market Cap (₹ Cr.) 679
Equity (₹ Cr.) 3.1
Face Value (₹) 5
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Net Interest Income (₹ Cr.)18.4 21.921.4 22.422.7 28.523.7 35
Interest Earned (₹ Cr.)41.4 40.845.3 37.547.8 30.749.4 26.1
Total Income (₹ Cr.)401 24.1437 25.4455 27461 24.6
Adj EPS (₹)3 14.32.9 29.82.5 8.12.8 1.5
NIM (%)0.00 -0.00 -0.00 -0.00 -
Net NPA to Net Advances (%)0 -0 -0 -0 -
CASA (%)21.00 -0.00 -0.00 -0.00 -

Management X-Ray of NGL Fine-Chem:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:72.74%Institutions:0.04%Non-Institutions:27.22%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%20%40%60%80%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of NGL Fine-Chem

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of NGL Fine-Chem

Adj EPS (Rs.)

Price Chart, Live Stock Chart, Technical Chart of

Sales (Cr.)

Price Chart, Live Stock Chart, Technical Chart of

ROE (%)

Price Chart, Live Stock Chart, Technical Chart of

ROCE (%)

Price Chart, Live Stock Chart, Technical Chart of
Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales8896100114153152258319275329
Operating Expenses 73747492121131181253246284
Manufacturing Costs13131518222733505063
Material Costs424138466365103148140155
Employee Cost 9111418212427333441
Other Costs 910810151619222325
Operating Profit 15222522322177662945
Operating Profit Margin (%) 16.9%22.8%25.5%19.0%21.1%13.7%29.8%20.7%10.4%13.6%
Other Income 001343913816
Interest 2212332222
Depreciation 3335677888
Exceptional Items 2000000000
Profit Before Tax 13182318281476692751
Tax 5685742117612
Profit After Tax 8111513201155522039
PAT Margin (%) 9.4%11.8%14.9%11.1%13.1%7.0%21.5%16.4%7.3%11.7%
Adjusted EPS (₹)13.518.524.120.532.617.289.884.632.662.4
Dividend Payout Ratio (%)0%0%0%0%5%10%2%2%5%3%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 3344597292101155207226263
Share Capital 3333333333
Reserves 304156698998152203222260
Minority Interest0000000000
Debt11132024232311273032
Long Term Debt20912886321
Short Term Debt1012111115155232832
Trade Payables17141424162127352347
Others Liabilities 57171418111210911
Total Liabilities 6778111133149156206278288353

Fixed Assets

Gross Block2938286474818592100108
Accumulated Depreciation111337132027334148
Net Fixed Assets17242556616158595960
CWIP 1216300162646
Investments 236691433324357
Inventories12101217192838552743
Trade Receivables26323028332638656583
Cash Equivalents 22243351132
Others Assets642019252334605463
Total Assets 6778111133149156206278288353

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 88102292027163211
PBT 13182318281476692751
Adjustment 3335811376-1
Changes in Working Capital -4-6-84-19-2-32-436-26
Tax Paid -5-6-8-5-7-4-21-17-6-12
Cash Flow From Investing Activity -3-10-10-21-10-19-24-16-24-17
Capex -3-10-18-23-14-7-5-14-29-28
Net Investments 00100-41000
Others 00725-8-20-2511
Cash Flow From Financing Activity -42000-1-1-1-1-1
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -2-100000000
Interest Paid 0000000000
Dividend Paid 00000-1-1-1-1-1
Others -2300000000
Net Cash Flow 1001-102-17-7
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)29.0429.5928.7319.2224.5210.9743.2228.869.3115.78
ROCE (%)33.0337.1433.821.6827.6313.6551.934.7111.518.93
Asset Turnover Ratio1.571.441.130.951.0811.431.320.971.03
PAT to CFO Conversion(x)10.730.671.690.451.820.490.311.60.28
Working Capital Days
Receivable Days9510310791727145598682
Inventory Days39393745425646535439
Payable Days1191231231451119774657183

NGL Fine-Chem Ltd Stock News

NGL Fine-Chem Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of NGL Fine-Chem on 21-Feb-2025 16:59 is ₹1,099.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of NGL Fine-Chem stood at ₹678.9.
The latest P/E ratio of NGL Fine-Chem as of 21-Feb-2025 16:59 is 23.01.
The latest P/B ratio of NGL Fine-Chem as of 21-Feb-2025 16:59 is 2.42.
The 52-week high of NGL Fine-Chem is ₹2,822.5 and the 52-week low is ₹962.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of NGL Fine-Chem is ₹361.9 ( Cr.) .

About NGL Fine-Chem Ltd

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on